IL-1

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

Related to IL-1: Il-6, IL-2, Cytokines, IL-8, Interleukin 1, IL-1 beta

IL-1

IL1B

A gene on chromosome 2q14 that encodes interleukin-1B, a cytokine produced by activated macrophages as a proprotein, which is proteolytically activated by caspase 1 (CASP1/ICE). IL-1B is a key mediator of inflammation and is involved in an array of cellular activities, including cell proliferation, differentiation and apoptosis.

IL-1

Leukocyte-activating factor An 11 kD cytokine produced by a wide range of cells; IL-1 elicits the acute phase response, acts on the CNS as a pyrogen, stimulates fibroblast, B- and T-cell proliferation and differentiation, ↑ lymphokine, collagenase and PG production, activity of NK cells against tumor targets, stimulates myocytolysis–via PGs, elicits hormone release from the pituitary, evokes the release of PMNs from the BM, and PMN degranulation, ↑ oxidase activity and hexose monophosphate shunt activity; in synovial cells, IL-1 stimulates proliferation and production of collagen, PG, and plasminogen activator IL-1 production Stimulated by various agents–eg, calcium ionophores, IFN-α, IFN-γ, lipopolysaccharides, muramyl dipeptide, aluminum hydroxide, phorbol myristate acetate, staphylococci, silica, and others; inhibited by corticosteroids, PGE₂–via the cyclooxygenase pathway, suppressor T cells, and cyclosporine–which specifically inhibits T cell-induced IL-1 production IL-1 & disease IL-1 may have a role in

1. Type 1 DM, ↑ IL-1
production by macrophages in the early β-cell destructive lesions of type 1 DM.

2. ASHD–n-3 fish oils ↓ circulating IL-1.

3. Rheumatoid arthritis–IL-1 acts with substance P.

IL-1

α Therapeutic uses IL-1α is reportedly effective in accelerating recovery of platelet counts after high-dose carboplatin and may be useful in thrombocytopenia induced by chemotherapy

IL-1

see interleukins.

References in periodicals archive ?

Single nucleotide polymorphisms in intron 2 of the human interleukin-1 receptor antagonist (IL-1Ra) gene: further definition of the IL-1 R and IL-1Ra polymorphisms in North American Caucasians and Taiwanese Chinese.

Allelic frequencies of IL-1 polymorphisms in several ethnic populations.

Frequencies of interleukin 1 gene polymorphisms in Koreans

All pre-specified secondary and exploratory endpoints in both studies demonstrated statistically significant effects of the IL-1 Trap compared to placebo.

Regeneron Reports Positive Phase 3 Data for IL-1 Trap in CAPS

This, say the scientists, is evidence that IL-1 does not act directly on the pituitary, but instead acts on the brain, which then sends CRF to the pituitary as a secondary messenger to switch on ACTH release.

Interleukin-1's secret message to ACTH

The IL-1 Trap is designed to attach to and neutralize IL-1 in the blood stream before it can attach to cell-surface receptors and generate signals that can trigger disease in body tissue.

Regeneron Receives Fast-Track Designation for the IL-1 Trap in CIAS1-Associated Periodic Syndromes (CAPS); Data from Pivotal Trial Expected in Second Half of 2006

IL-1 is a soluble protein secreted by certain cells in the body.

Regeneron Completes Enrollment for IL-1 Trap Phase 3 Trial in Autoinflammatory Disease; Efficacy Phase of Trial on Target for Completion in 2006

In addition, at the American Heart Association Scientific Sessions meeting in November 2005, the Company will report positive preliminary data from a pilot study indicating that the IL-1 Trap provided prolonged suppression of C-reactive Protein (CRP), a marker of inflammation, in otherwise healthy adults.

VEGF Trap Oncology Program with Sanofi-Aventis Planned to Expand Rapidly; Regeneron Updates Clinical Programs and Financial Guidance

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation, our ability to screen nutritional compounds for their effects on inflammatory responses, given specific IL-1 genetic patterns and our ability to make progress in advancing our core technologies.

Interleukin Genetics Receives Patent for Pharmacogenetic Tests for Asthma to Guide Selection of Drugs and Prediction of Asthma Severity

After evaluating the results of the Phase II study, Novartis informed Regeneron that as a condition for participating in the continued clinical development of the IL-1 Trap, it would require revisions to the terms of the original agreement applicable to the IL-1 Trap.

Regeneron Announces Plans for Phase IIb Study of IL-1 Trap and End of Novartis Participation in IL-1 Trap Program

Since the IL-1 SNPs that an individual is born with do not change, they may be used to predict risk for osteoporosis at any age and to guide development and aid individuals' selection of preventive therapies prior to the development of symptoms.

Interleukin Genetics to Collaborate with University of California, San Francisco on Osteoporosis Genetics

We plan to develop interventions to help the roughly 30% of individuals who are IL-1 positive to reduce their increased risk for the disease.

Interleukin Genetics Receives Patent for Variations -SNPs- in Inflammation Gene That Indicate Increased Risk for Osteoporosis

Interleukin Genetics (NASDAQ:ILGN) announced today preliminary results of an economic modeling study that indicate the use of pharmacogenetic testing to determine specific IL-1 gene variations may be a cost-effective tool for determining the best course of therapy for rheumatoid arthritis (RA) patients.

Interleukin Genetics and ScHARR Economic Modeling Study Demonstrates Potential Cost Benefit of IL-1 Pharmacogenetic Testing before Rheumatoid Arthritis Treatment